The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer
Open accessAbstract
Nanotechnology has tremendous potential to contribute to cancer immunotherapy. The “in situ vaccination” immunotherapy strategy directly manipulates identified tumours to overcome local tumour-mediated immunosuppression and subsequently stimulates systemic anti-tumour immunity to treat metastases. We show that inhalation of self-assembling virus-like nanoparticles from Cowpea Mosaic Virus (CPMV) reduces established B16F10 lung melanoma and simultaneously generates potent systemic anti-tumour immunity against poorly immunogenic B16F10 in the skin. Full efficacy required Il-12, Ifn-γ, adaptive immunity, and neutrophils. Inhaled CPMV nanoparticles were rapidly taken up by and activated neutrophils in the tumour microenvironment as an important part of the anti-tumour immune response. CPMV also exhibited clear treatment efficacy and systemic anti-tumour immunity in ovarian, colon, and breast tumour models in multiple anatomic locations. CPMV nanoparticles are stable, nontoxic, modifiable with drugs and antigens, and their nanomanufacture is highly scalable. These properties, combined with their inherent immunogenicity and demonstrated efficacy against a poorly immunogenic tumour, make CPMV an attractive and novel immunotherapy against metastatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
Neutrophils in the activation and regulation of innate and adaptive immunity
Mantovani, A., Cassatella, M. A., Costantini, C., & Jaillon, S. (2011) · Nature Reviews Immunology · doi:10.1038/nri3024 · Cited by 3,027
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Andtbacka, R. H. I., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3377 · Cited by 2,634
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
Vimentin in cancer and its potential as a molecular target for cancer therapy
Satelli, A., & Li, S. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0735-1 · Cited by 1,557
Pulaski, B. A., & Ostrand‐Rosenberg, S. (2000) · Current Protocols in Immunology · doi:10.1002/0471142735.im2002s39 · Cited by 912
Evidence for a cross-talk between human neutrophils and Th17 cells
Pelletier, M., Maggi, L., Micheletti, A., Lazzeri, E., Tamassia, N., Costantini, C., Cosmi, L., Lunardi, C., Annunziato, F., Romagnani, S., et al. (2010) · Blood · doi:10.1182/blood-2009-04-216085 · Cited by 782
Jablonska, J., Leschner, S., Westphal, K., Lienenklaus, S., & Weiss, S. (2010) · Journal of Clinical Investigation · doi:10.1172/jci37223 · Cited by 564
Gene-engineered T cells for cancer therapy
Kershaw, M. H., Westwood, J. A., & Darcy, P. K. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3565 · Cited by 505
Kuang, D.-M., Zhao, Q., Wu, Y., Peng, C., Wang, J., Xu, Z., Yin, X.-Y., & Zheng, L. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.041 · Cited by 499
Winograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0215 · Cited by 459
Conejo-Garcia, J. R., Benencia, F., Courreges, M.-C., Kang, E., Mohamed-Hadley, A., Buckanovich, R. J., Holtz, D. O., Jenkins, A., Na, H., Zhang, L., et al. (2004) · Nature Medicine · doi:10.1038/nm1097 · Cited by 437
van Gisbergen, K. P. J. M., Sanchez-Hernandez, M., Geijtenbeek, T. B. H., & van Kooyk, Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041276 · Cited by 402
Inhibition of tumor growth by elimination of granulocytes.
Pekarek, L. A., Starr, B. A., Toledano, A. Y., & Schreiber, H. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.1.435 · Cited by 340
Neutrophils efficiently cross-prime naive T cells in vivo
Beauvillain, C., Delneste, Y., Scotet, M., Peres, A., Gascan, H., Guermonprez, P., Barnaba, V., & Jeannin, P. (2007) · Blood · doi:10.1182/blood-2006-12-063826 · Cited by 315
Abi Abdallah, D. S., Egan, C. E., Butcher, B. A., & Denkers, E. Y. (2011) · International Immunology · doi:10.1093/intimm/dxr007 · Cited by 264
Wislez, M., Rabbe, N., Marchal-Sommé, J., Milleron, B. J., Crestani, B., Mayaud, C. M., Antoine, M., Soler, P., & Cadranel, J. L. (2003) · PubMed · Cited by 243
CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2014.00385 · Cited by 224
Cytokine inhibition in the treatment of COPD
Chung, K. F., Caramori, G., Adcock, I., & Di Stefano, A. (2014) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s42544 · Cited by 163
Innate Immunity Mediates Follicular Transport of Particulate but Not Soluble Protein Antigen
Link, A., Zabel, F., Schnetzler, Y., Titz, A., Brombacher, F., & Bachmann, M. F. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103312 · Cited by 162
Baird, J. R., Byrne, K. T., Lizotte, P. H., Toraya‐Brown, S., Scarlett, U. K., Alexander, M. P., Sheen, M. R., Fox, B. A., Bzik, D. J., Bosenberg, M., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201209 · Cited by 140
Self-citationScarlett, U. K., Cubillos‐Ruiz, J. R., Nesbeth, Y. C., Martinez, D. G., Engle, X. A., Gewirtz, A. T., Ahonen, C. L., & Conejo-Garcia, J. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0835 · Cited by 137
Halperin, S. A., Ward, B. J., Cooper, C., Predy, G., Díaz‐Mitoma, F., Dionne, M., Embreé, J., McGeer, A., Zickler, P., Moltz, K.-H., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.087 · Cited by 136
Wiley, J. A., Richert, L. E., Swain, S. D., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007142 · Cited by 130
Baird, J. R., Fox, B. A., Sanders, K. L., Lizotte, P. H., Cubillos‐Ruiz, J. R., Scarlett, U. K., Rutkowski, M. R., Conejo-Garcia, J. R., Fiering, S., & Bzik, D. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1974 · Cited by 127
Self-citationIL-10 Immunomodulation of Myeloid Cells Regulates a Murine Model of Ovarian Cancer
Hart, K. M., Byrne, K. T., Molloy, M. J., Usherwood, E., & Berwin, B. L. (2011) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00029 · Cited by 124
Neutrophil activation and survival are modulated by interaction with NK cells
Costantini, C., Micheletti, A., Calzetti, F., Perbellini, O., Pizzolo, G., & Cassatella, M. A. (2010) · International Immunology · doi:10.1093/intimm/dxq434 · Cited by 121
Cowpea Mosaic Virus Nanoparticles Target Surface Vimentin on Cancer Cells
Steinmetz, N. F., Cho, C., Ablack, A. L., Lewis, J. D., & Manchester, M. (2011) · Nanomedicine · doi:10.2217/nnm.10.136 · Cited by 118
Self-citationAli, O. A., Verbeke, C., Johnson, C., Sands, R. W., Lewin, S. A., White, D. A., Doherty, E. J., Dranoff, G., & Mooney, D. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0777 · Cited by 108
Biomimetic Antigenic Nanoparticles Elicit Controlled Protective Immune Response to Influenza
Patterson, D. P., Rynda‐Apple, A., Harmsen, A. L., Harmsen, A. G., & Douglas, T. (2013) · ACS Nano · doi:10.1021/nn4006544 · Cited by 107
Lizotte, P. H., Baird, J. R., Stevens, C. A., Lauer, P., Green, W. R., Brockstedt, D. G., & Fiering, S. (2014) · OncoImmunology · doi:10.4161/onci.28926 · Cited by 89
Self-citationGonzález, M. J., Plummer, E. M., Rae, C. S., & Manchester, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007981 · Cited by 66
Lebel, M., Daudelin, J., Chartrand, K., Tarrab, E., Kalinke, U., Savard, P. E., Labrecque, N., Leclerc, D., & Lamarre, A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1302030 · Cited by 63
Aire Deficiency Promotes TRP-1–Specific Immune Rejection of Melanoma
Zhu, M., Nagavalli, A., & Su, M. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3781 · Cited by 62
Virus-Like Particles as Antigenic Nanomaterials for Inducing Protective Immune Responses in The Lung
Rynda‐Apple, A., Patterson, D. P., & Douglas, T. (2014) · Nanomedicine · doi:10.2217/nnm.14.107 · Cited by 50
Huber, B., Schellenbacher, C., Jindra, C., Fink, D., Shafti‐Keramat, S., & Kirnbauer, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120152 · Cited by 41
Clancy‐Thompson, E., King, L. K., Nunnley, L. D., Mullins, I. M., Slingluff, C. L., & Mullins, D. W. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0084 · Cited by 37
Stimulating antitumor immunity with nanoparticles
Sheen, M. R., Lizotte, P. H., Toraya‐Brown, S., & Fiering, S. (2014) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1274 · Cited by 28
Self-citationRynda‐Apple, A., Dobrinen, E., McAlpine, M., Read, A., Harmsen, A. L., Richert, L. E., Calverley, M., Pallister, K. B., Voyich, J. M., Wiley, J. A., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.03.018 · Cited by 25
Richert, L. E., Rynda‐Apple, A., Harmsen, A. L., Han, S., Wiley, J. A., Douglas, T., Larson, K., Morton, R. V., & Harmsen, A. G. (2013) · European Journal of Immunology · doi:10.1002/eji.201343587 · Cited by 11
Cited by
Designer vaccine nanodiscs for personalized cancer immunotherapy
Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A., & Moon, J. J. (2017) · Nature Materials · doi:10.1038/nmat4822 · Cited by 1,056
Enhancing cancer immunotherapy with nanomedicine
Irvine, D. J., & Dane, E. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 882
Nooraei, S., Bahrulolum, H., Hoseini, Z. S., Katalani, C., Hajizade, A., Easton, A. J., & Ahmadian, G. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00806-7 · Cited by 869
Recent progress in drug delivery
Li, C., Wang, J., Wang, Y., Gao, H., Wei, G., Huang, Y., Yu, H., Gan, Y., Wang, Y., Mei, L., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.003 · Cited by 818
Shae, D., Becker, K. W., Christov, P., Yun, D. S., Lytton-Jean, A. K. R., Sevimli, S., Ascano, M., Kelley, M., Johnson, D. B., Balko, J. M., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0342-5 · Cited by 668
Metadata
- Authors
- Lizotte, P. H., Wen, A. M., Sheen, M. R., Fields, J., Rojanasopondist, P., Steinmetz, N. F., & Fiering, S.
- Venue
- Nature Nanotechnology
- Published
- 2015-12-21
- Volume
- 11
- Issue
- 3
- Pages
- 295-303
- ISSN
- 1748-3387 (ISSN-L)
- 1748-3395
- OpenAlex
- W2255455792
- Cited by
- 485
- References
- 45
- FWCI
- 13.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.